Efficacy and Tolerability of Ophthalmic Epinastine Assessed Using the Conjunctival Antigen Challenge Model in Patients with a History of Allergic Conjunctivitis

Clinical Therapeutics

Volumn 26, Issue 1, 2004, Pages 35-47

  Abelson, Mark B ^a,b,c   Gomes, Paul ^a   Crampton, H Jerome ^a   Schiffman, Rhett M ^d   Bradford, Ron R ^d   Whitcup, Scott M ^d  

^a Ophthalmic Research Associates   (United States)

^b SCHEPENS EYE RESEARCH INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d ALLERGAN INC   (United States)

Author keywords

Allergic conjunctivitis; Conjunctival antigen challenge; Epinastine; Ophthalmic solution

Indexed keywords

ANTIGEN; CONJUNCTIVAL ANTIGEN; EPINASTINE; EYE DROPS; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ALLERGIC CONJUNCTIVITIS; ANAMNESIS; ARTICLE; CHEMOSIS; CHILD; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; EYELID; FEMALE; HUMAN; HYPEREMIA; LACRIMATION; MAJOR CLINICAL STUDY; MALE; OCULAR PRURITUS; PHASE 3 CLINICAL TRIAL; PROVOCATION TEST; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SCREENING; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

EID: 1242294540     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(04)90004-5     Document Type: Article

References (22)

1. Trocme SD, Sra KK. Spectrum of ocular allergy. Curr Opin Allergy Immunol. 2002;2:423-427.
2. Abelson MB, ed. Allergic Diseases of the Eye. Philadelphia, Pa: WB Saunders; 2000.
3. Bacon AS, Ahluwalia P, Irani AM, et al. Tear and conjunctival changes during the allergen-induced early-and late-phase responses. J Allergy Clin Immunol. 2000; 106:948-954.
4. Bielory L. Allergic and immunological disorders of the eye. Part II: Ocular allergy. J Allergy Clin Immunol. 2000; 106:1019-1032.
5. Fugner A, Bechtel WD, Kuhn FJ, Mierau J. In vitro and in vivo studies of the non-sedating antihistamine epinastine. Arzneimittelforschung. 1988;38:1446-1453.
6. 1-receptor occupancy in human subjects treated with epinastine, a second-generation antihistamine. Methods Find Exp Clin Pharmacol. 1995;17(Suppl C):64-69.
7. 1 receptor antagonist, epinastine (WAL 801 CL), on isolated human allergic effector cells. Inflamm Res. 2000;49:112-116.
8. Fukuishi N, Kan T, Hirose K, et al. Inhibitory effect of epinastine on superoxide generation by rat neutrophils. Jpn J Pharmacol. 1995;68:449-452.
9. Kamei C, Akagi M, Mio M, et al. Antiallergic effect of epinastine (WAL 801 CL) on immediate hypersensitivity reactions: (I). Elucidation of the mechanism for histamine release inhibition. Immunopharmacol Immunotoxicol. 1992; 14:191-205.
10. Kohyama T, Takizawa H, Akiyama N, et al. A novel antiallergic drug epinastine inhibits IL-8 release from human eosinophils. Biochem Biophys Res Commun. 1997;230:125-128.
11. Matsushita N, Aritake K, Takada A, et al. Pharmacological studies on the novel antiallergic drug HQL-79: II. Elucidation of mechanisms for antiallergic and antiasthmatic effects. Jpn J Pharmacol. 1998;78: 11-22.
12. 1 receptor antagonists epinastine, ketotifen and oxatomide in human leukocytes. Arzneimittelforschung. 1995;45:36-40.
13. Ohmori K, Manabe H, Akuta-Ohnuma K. Inhibitory effect of oxatomide on oxygen-radical generation and peptide-leukotnene release from guinea pig eosinophils. Arzneimittelforschung. 1998;48:43-46.
14. Tasaka K, Akagi M, Izushi K, Aoki I. Antiallergic effect of epinastine: The elucidation of the mechanism. Pharmacometrics. 1990;39:365-373.
15. Endo T, Moriyama H, Yamaguchi N, et al. Clinical effect of epinastine on Japanese cedar pollinosis: Comparison between early and late administration. Otorhinolaryngology (Tokyo). 1995;38:800-817.
16. Okuda M, Saito H, Furuuchi I, et al. Clinical effects of epinastine in perennial allergic rhinitis: A double-blind study in comparison with azelastine. Otorhinolaryngology (Tokyo). 1992;35(Suppl 4):289-312.
17. Tasaka K. Epinastine: An update of its pharmacology, metabolism, clinical efficacy and tolerability in the treatment of allergic diseases. Drugs Today. 2000;36: 735-757.
18. Yu D, Tang-Liu D. Ocular administration of epinastine to patients with allergic conjunctivitis: Pharmacokinetics and safety profile. In: Program and abstracts of the Annual Meeting of the Association for Research in Vision and Ophthalmology; Ft. Lauderdale, Fla; May 7, 2003. Abstract 3731.
19. Abelson MB, Chambers WA, Smith LM. Conjunctival allergen challenge. A clinical approach to studying allergic conjunctivitis. Arch Ophthalmol. 1990;108:84-88.
20. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol. 1985;103:1796-1806.
21. Abelson MB. Comparison of the conjunctival allergen challenge model with the environmental model of allergic conjunctivitis. Acta Ophthalmol Scand Suppl. 1999:38-42.
22. Whitcup SM, Bradford R, Lue J, et al. Efficacy and tolerability of ophthalmic epinastine: A randomized, double-masked, parallel-group, active-and vehicle-controlled environmental trial in patients with seasonal allergic conjunctivitis. Clin Ther. 2004;26:29-34.